{
    "nct_id": "NCT06793215",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2025-01-27",
    "study_start_date":null,
    "study_completion_date":null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Cisplatin"
            },
            {
                "drug_name": "Drug: Pembrolizumab"
            },
            {
                "drug_name": "Drug: Divarasib"
            },
            {
                "drug_name": "Drug: Pemetrexed"
            },
            {
                "drug_name": "Drug: Carboplatin"
            }
        ]
    },
    "long_title": "A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",
    "last_updated": "2025-10-06",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Hoffmann-La Roche",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 600,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "* Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy",
        "* Measurable disease, as defined by RECIST v1.1",
        "* No prior systemic treatment for advanced or metastatic NSCLC",
        "* Documentation of the presence of a KRAS G12C mutation",
        "* Documentation of known PD-L1 expression status in tumor tissue",
        "* Availability of a representative tumor specimen",
        "* Adequate end-organ function",
        "* Eligible to receive a platinum-based chemotherapy regimen",
        "Exclude - Exclusion Criteria Related to NSCLC:",
        "Exclude - * Known concomitant second oncogenic driver with available targeted treatment",
        "Exclude - * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases",
        "Exclude - * Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \\>=2 weeks prior to randomization",
        "Exclude - * History of leptomeningeal disease",
        "Exclude - * Uncontrolled tumor-related pain",
        "Exclude - * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently)",
        "Exclude - Exclusion Criteria Related to Current or Prior Treatments:",
        "Exclude - * Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of antineoplastic therapy while in the study",
        "Exclude - * Radiation therapy including palliative RT to bone metastases within 2 weeks prior to randomization and RT to the lung \\>30Gy within 6 months prior to randomization",
        "Exclude - * Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors",
        "Exclude - * Treatment with systemic immunosuppressive or immunostimulatory medications, including CD137 agonists and immune checkpoint inhibitors",
        "Exclude - * Current treatment with medications that are well known to prolong the QT interval",
        "Exclude - * Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to randomization",
        "Exclude - * Prior allogeneic stem cell or solid organ transplantation",
        "Exclude - Exclusion Criteria Related to General Health:",
        "Exclude - * History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival \\[OS\\] rate \\>90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer",
        "Exclude - * Individuals with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or any active bowel inflammation (including diverticulitis), malabsorption syndrome, conditions that would interfere with enteral absorption",
        "Exclude - * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest computed tomography scan",
        "Exclude - * Significant cardiovascular disease within 3 months prior to screening"
    ],
    "short_title": "A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Hoffmann-La Roche",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Divarasib + Pembrolizumab",
                        "arm_internal_id": 0,
                        "arm_description": "Participants will receive divarasib orally, once daily (QD) and pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W)",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Divarasib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Pembrolizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Pembrolizumab + Pemetrexed + Carboplatin or Cisplatin",
                        "arm_internal_id": 1,
                        "arm_description": "Participants will receive pembrolizumab, pemetrexed and carboplatin or cisplatin via IV infusion Q3W",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Pembrolizumab",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Pemetrexed",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Carboplatin",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "3",
                                "level_description": "Drug: Cisplatin",
                                "level_internal_id": 3,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "and": [
                                    {
                                        "or": [
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Lung Adenocarcinoma In Situ"
                                                }
                                            },
                                            {
                                                "clinical": {
                                                    "oncotree_primary_diagnosis": "Non-Small Cell Lung Cancer"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "clinical": {
                                            "age_numerical": ">=18",
                                            "disease_status": [
                                                "Advanced",
                                                "Metastatic"
                                            ]
                                        }
                                    }
                                ]
                            },
                            {
                                "and": [
                                    {
                                        "or": [
                                            {
                                                "genomic": {
                                                    "hugo_symbol": "KRAS",
                                                    "variant_category": "Mutation"
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "and": [
                                            {
                                                "genomic": {
                                                    "hugo_symbol": "EGFR",
                                                    "variant_category": "!Mutation"
                                                }
                                            },
                                            {
                                                "genomic": {
                                                    "hugo_symbol": "ALK",
                                                    "variant_category": "!Mutation"
                                                }
                                            },
                                            {
                                                "genomic": {
                                                    "hugo_symbol": "ROS1",
                                                    "variant_category": "!Mutation"
                                                }
                                            },
                                            {
                                                "genomic": {
                                                    "hugo_symbol": "BRAF",
                                                    "variant_category": "!Mutation"
                                                }
                                            },
                                            {
                                                "genomic": {
                                                    "hugo_symbol": "MET",
                                                    "variant_category": "!Mutation"
                                                }
                                            }
                                        ]
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}
